- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation (CNV)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Brolucizumab – November 2019
Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu®
Last updated
20 March 2020